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Contextandobjective:Nocurrentbiomarker can reliablypredict visceral and liver fat content, both
of which are risk factors for cardiovascular disease. Vagal tone has been suggested to influence
regional fat deposition. Pancreatic polypeptide (PP) is secreted from the endocrine pancreas under
vagal control. We investigated the utility of PP in predicting visceral and liver fat.
Patients and Methods: Fasting plasma PP concentrations were measured in 104 overweight and
obese subjects (46 men and 58 women). In the same subjects, total and regional adipose tissue,
including total visceral adipose tissue (VAT) and total subcutaneous adipose tissue (TSAT), were
measuredusingwhole-bodymagnetic resonance imaging. Intrahepatocellular lipid content (IHCL)
was quantified by proton magnetic resonance spectroscopy.
Results: Fasting plasma PP concentrations positively and significantly correlated with both VAT (r 
0.57, P .001) and IHCL (r 0.51, P .001), but not with TSAT (r 0.02, P .88). Fasting PP concen-
trations independently predicted VAT after controlling for age and sex. Fasting PP concentrations
independently predicted IHCL after controlling for age, sex, bodymass index (BMI), waist-to-hip ratio,
homeostatic model assessment 2-insulin resistance, (HOMA2-IR) and serum concentrations of triglyc-
eride (TG), total cholesterol (TC), and alanine aminotransferase (ALT). Fasting PP concentrations were
associatedwith serumALT, TG, TC, low- and high-density lipoprotein cholesterol, and blood pressure
(P  .05). These associations were mediated by IHCL and/or VAT. Fasting PP and HOMA2-IR were
independently significantly associated with hepatic steatosis (P  .01).
Conclusions: Pancreatic polypeptide is a novel predictor of visceral and liver fat content, and thus
apotential biomarker for cardiovascular risk stratificationand targeted treatmentof patientswith
ectopic fat deposition. (J Clin Endocrinol Metab 100: 1048–1052, 2015)
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characteristic; TC, total cholesterol; TG, triglyceride; TSAT, total subcutaneous adipose
tissue; VAT, visceral adipose tissue; WHR, waist-to-hip ratio.
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It is increasingly recognized that obesity is not a homo-geneous condition and that cardiovascular risk can
vary between individuals with a similar body mass index
(BMI) (1). Variation in body fat distribution is an impor-
tant determinant of cardiometabolic risk among patients
with obesity. The intra-abdominal visceral deposition of
fat is a major contributor to the development of insulin
resistance, diabetes mellitus, hyperlipidemia, and hyper-
tension (2). Visceral adipose tissue (VAT) and intrahepa-
tocellular lipid content (IHCL) are independently and
more strongly associated with an adverse metabolic risk
profile than sc adipose tissue (3).
Regional body fat distribution and ectopic fat deposi-
tion can be identified using magnetic resonance imaging
and proton magnetic resonance spectroscopy (4). How-
ever, such methods require significant technical and fi-
nancial resources. There is therefore a need formore easily
measured biomarkers that predict the extent of visceral
and liver fat deposition, and which can thus be used to
identify individuals at higher risk of metabolic or cardio-
vascular disease.
Pancreatic polypeptide (PP) is a member of the PP fold
peptide family and is secreted postprandially fromPP cells
of the pancreatic islets of Langerhans. PP has been shown
to inhibit food intake, gastric emptying, pancreatic exo-
crine secretion, and gallbladder contraction (5). PP secre-
tion is thought to be primarily under vagal control (6). PP
concentrations following an iv glucose injection have been
reported to beweakly associatedwith intra-abdominal fat
asmeasured by computed tomography in human subjects,
although this association was not independent of age or
sex (7). However, iv glucose has been reported to modu-
late circulating PP concentrations (8), and fasting PP con-
centrationsmay better reflect intra-abdominal vagal tone.
Furthermore, intrahepatic fat has been suggested to be a
better marker of obesity-associated metabolic complica-
tions than visceral fat (9).Wehypothesized that variations
in visceral parasympathetic activitywould alter bothVAT
deposition and PP release, and thus that obese individuals
with increased visceral and liver fat content could be iden-
tified by their elevated plasma PP concentrations.
Materials and Methods
Participants
Participants took part in studies at Imperial College London
and University of Surrey that had all been approved by local
Research and Ethics committees and were performed according
to the principles of the Declaration of Helsinki between Decem-
ber 2007 and September 2012. Subjects were recruited through
local advertising and from the obesity clinic. Exclusion criteria
included diabetes mellitus, intercurrent/chronic medical or psy-
chiatric illness, pregnancy, or alcohol or substance abuse. Writ-
ten informed consent was obtained from all subjects. Anthro-
pometric measurements (weight, height, waist, and hip
circumference) were made, and BMI and waist-to-hip ratio
(WHR) calculated.
Biochemical measurements
Blood samples for PP measurement were collected, centri-
fuged at 4°C and plasma separated and stored at20°C before
being assayed in duplicate using an established in-house RIA in
the Section of Investigative Medicine, Imperial College London
(10) (Supplemental Data). To establish the potential variability
of PPmeasurement in samples collected using differentmethods,
we investigated the effect of the type of tube used for sample
collection, time between blood collection and plasma/serum sep-
aration, and freeze-thawcycles onplasmaPPmeasurements.The
type of tube used to collect blood samples (lithium heparin, lith-
ium heparin tubes containing aprotinin [Trasylol], ethylenedi-
aminetetraacetic acid, plain, and serum separation tubes), the
time between blood collection and plasma and serum separation
(up to 4 and 5 h, respectively) and freeze-thaw cycle number (up
to four) had no significant effect on measured plasma PP con-
centrations (Supplemental Table 2 and Supplemental Figure 1).
Plasma insulin, glucose, cholesterol, triglycerides (TG), and
alanine aminotransferase (ALT) concentrations were analyzed
using an Abbott Architect ci8200 analyzer (Abbott Diagnostics)
and Advia 1800 Chemistry System (Siemens Healthcare Diag-
nostics). Serum insulin was measured using an Abbott Architect
ci8200 analyzer (Abbott Diagnostics) and a RIA kit (Millipore
Corporation). Fasting insulin and glucose were used to calculate
homeostatic model assessment 2-insulin resistance (HOMA2-
IR) (11).
Magnetic resonance imaging and spectroscopy of
liver fat
Rapid T1-weighted magnetic resonance images were ac-
quired using a 1.5T Phillips Achiva scanner (Phillips), as previ-
ously described (12). Total and regional adipose tissue volumes
(sc and internal, both further separated into abdominal and non-
abdominal compartments) were measured as previously defined
(4, 12). Intra-abdominal adipose tissue is referred to as visceral
adipose tissue. Intrahepatocellular lipid content (IHCL) was
quantified by proton magnetic resonance spectroscopy as pre-
viously described (13).
Statistical analysis
Analyses were performed using Prism version 5.1 software
(GraphPadSoftware) and IBMSPSSStatistics version22. Sample
size calculation showed that 92 subjects were required for a
power of 80%, significance level () of 0.05, nine independent
variables, and a multiple regression coefficient (R) of 0.4. Nor-
mally distributed data are presented as mean SD and nonnor-
mally distributed data as median (interquartile range). The stu-
dent t test andMann-WhitneyU testwere used to test differences
betweennormallydistributedandnon-normallydistributeddata
sets, respectively. Associations between plasma PP and BMI, to-
tal sc adipose tissue, VAT, IHCL, and fasting insulin concentra-
tions were examined using Spearman’s rank correlation. Data
that were not normally distributed were log transformed when
necessary. Multiple regression analysis was used to examine the
association between fasting plasmaPP and bothVATand IHCL,
adjusting for a number of potential confounding variables. Lo-
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gistic regression was used to examine the predictive ability of PP
and HOMA2-IR in the diagnosis of hepatic steatosis. P  .05
was considered statistically significant.
Results
Forty-six men and 58 women were studied. Demographic,
anthropometric, and biochemical characteristics, and re-
gional fat distributions of the men and women in the study
populationaredescribedinSupplementalTable1.PlasmaPP
concentrationscorrelatedwithVAT(r0.57,P .001)and
IHCL (r 0.51, P .001). The correlation between fasting
PP and IHCL is shown in Supplemental Figure 1. There was
aweak but significant correlation between PP and BMI (r
0.24,P .02), but not betweenPP and sc adipose tissue (r
0.02, P .88). There was a significant correlation between
fasting PP and insulin concentrations (r  0.34, P  .001)
and between fasting insulin concentration and IHCL (r 
0.64, P .001) and VAT (r 0.55, P .001), as expected.
The correlation between fasting PP concentrations andVAT
or IHCL remained significant after controlling for fasting
plasma insulin concentrations (P .001).
PP and VAT
The association between fasting plasma PP concen-
trations and VAT was further analyzed, controlling for
age, sex, and HOMA2-IR (Tables 1 and 2). The asso-
ciation between fasting plasma PP and visceral adipose
tissue remained significant when age and sex were ad-
justed for in the analysis, but not after adjusting for
HOMA2-IR (P  .07).
PP and IHCL
Fasting plasma PP concentrations remained an indepen-
dent predictor of IHCL when age, sex, BMI, WHR,
HOMA2-IR,andserumconcentrationsofTG,TC,andALT
were controlled for (Table 2). Because IHCL was analyzed
on the log scale, the size of the effect is reported as a ratio.
Without any adjustments, a 10-pmol/L increase in PP was
associated with a 28% increase in IHCL. After adjustments
for all other variables, a 10-pmol/L increase in PP was asso-
ciated with a 12% increase in IHCL (Table 2).
Despite having the same BMI (33.0 vs 32.9, P  .71),
obese individualswithhepatic steatosis (n35, defined as
an IHCL 5.5%) (13, 14) had a significantly higher me-
dian fasting plasma PP than obese individuals without
hepatic steatosis (n  29, 34.84 vs 17.66 pmol/L, P 
.0002).
PP and cardiometabolic risk factors
Fasting plasma PP concentrations correlated with serum
ALT,TG,TC, low-density lipoproteincholesterol,high-den-
sity lipoprotein cholesterol, systolic blood pressure (BP) and
diastolic BP when no adjustments were made, but not after
adjusting for eitherorboth IHCLorvisceral fat (Supplemen-
tal Table 3).
PP and HOMA2-IR: Independent predictors of
hepatic steatosis
Table 3 shows the odds ratios (and corresponding con-
fidence intervals) quantifying the association between
each variable and the odds of hepatic steatosis. The area
under the receiver operating characteristic (ROC) curve
Table 1. Associations Between Fasting Plasma PP Concentrations and VAT, Adjusting for Age, Sex, and HOMA2-IR
Model Adjustments Coefficient (95% CI) P Value
1 None 0.35 (0.19–0.51) .001
2 Age 0.19 (0.04–0.34) .02
3 Model 2  sex 0.16 (0.03–0.29) .02
4 Model 3  HOMA2-IR 0.11 (0.01–0.23) .07
Abbreviation: CI, confidence interval.
The coefficients (and corresponding confidence intervals) indicate the change in VAT for a 10-pmol/L increase in fasting plasma PP concentrations.
Table 2. Associations between fasting plasma PP concentrations and IHCL, adjusting for age, sex, BMI, WHR,
HOMA2-IR, and serum concentrations of TG, TC, and ALT
Model Adjustments Ratio (95% CI) P Value
1 None 1.28 (1.17–1.40) .001
2 Age, Sex 1.17 (1.08–1.27) .001
3 Model 2  BMI, WHR, HOMA2-IR 1.11 (1.04–1.20) .004
4 Model 3  TG, total cholesterol 1.10 (1.03–1.18) .005
5 Model 4  ALT 1.12 (1.05–1.19) .001
Abbreviation: CI, confidence interval.
Because IHCL was analyzed on the log scale, the effect sizes are reported in the form of ratios. The ratios (and corresponding confidence intervals)
are reported for a 10-pmol/L increase in fasting PP concentration.
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(AUC) for each model is reported in Table 3. Both PP and
HOMA2-IR were independently significantly associated
with hepatic steatosis. The area under the ROC curve
(89%) was significantly higher for the combination of PP
and HOMA2-IR than for either PP or HOMA2-IR alone.
Discussion
We investigated the relationship between fasting plasma
PP concentrations, and regional fat distribution and liver
fat content. Fasting plasma PP concentrations were sig-
nificantly associated with visceral but not sc adipose tis-
sue. Visceral abdominal adiposity is strongly related to
cardiometabolic risk factors and the prevalence of cardio-
vascular disease (15).
In our study, the correlations between fasting plasma
PP concentrations and visceral/liver fat were more signif-
icant than that between fasting plasma PP concentrations
and BMI. Obese patients with hepatic steatosis had sig-
nificantly higher fasting plasma PP concentrations. Our
data suggest that PP is a marker of visceral/liver fat rather
than of BMI per se.
Fasting PP concentrations are a predictor of liver fat.
Ectopic fat in the liver may be more important than vis-
ceral fat in the determination of metabolically healthy in-
dividuals (16). Fatty liver is an independent predictor of
type2diabetes (17).There is currentlyno singlebiomarker
that can reliably detect liver fat, which is an independent
risk factor for cardiovascular disease (18). A liver fat score
incorporating information regardingwaist circumference,
serumTG, serumhigh-density lipoprotein cholesterol, BP,
fasting plasma glucose, type 2 diabetes, fasting serum in-
sulin, and liver transaminases has been reported to predict
nonalcoholic fatty liver disease and liver fat content (19).
Although we did not have data for all of the parameters
required for calculation of this liver fat score from our
study participants, and hence cannot compare its utility
for predicting liver fat with that of fasting plasma PP con-
centration, it would be interesting to directly compare
these methods in future studies. Circulating PP measure-
ment was not significantly influenced by a range of dif-
ferent collection methods, suggesting the collection of
samples suitable for PP measurement could be performed
in a routine clinical setting. Pancreatic polypeptide con-
centrationswere associatedwith a number of cardiometa-
bolic risk factors, including low-density lipoprotein cho-
lesterol, TG, and BP. These associationsweremediated by
visceral and/or liver fat. Unsurprisingly, HOMA2-IR, a
surrogate of insulin resistance, was a predictor of hepatic
steatosis. Interestingly, however, fasting PP was an inde-
pendent predictor of liver fat.
The increased PP levels associated with increased VAT
and IHCL may reflect increased abdominal parasympa-
thetic outflow (20). It is also possible that plasma PP levels
reflect basal insulin secretion, and that insulin drives ad-
ipogenesis in specific depots.However, the correlation be-
tween fasting PP concentrations and VAT or IHCL re-
mained significant after controlling for fasting plasma
insulin concentrations.
In conclusion, measurement of fasting plasma PP con-
centrations may be useful in the prediction of visceral and
IHCL content. Additional work is required to determine
whether fasting plasma PP can predict cardiovascular dis-
ease and help distinguish metabolically benign and
healthy obesity from metabolically abnormal normal
weight and obese subjects. Future studies could also in-
vestigate whether fasting PP concentrations can predict
response to bariatric surgery.
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